This is high risk stock. The company is moving as fast as data from their trials will allow. If that is too slow for you, then you need to sell. But they have a tremendous amount of potential. Their RCC drug Archexin has definitely the lowest amount of side-effects vs. the competitors. Now let's see the efficacy vs. the competitors. t
I know your background and I do respect you. I do however think that you have not kept up with recent advances i the RNA space. Why do you have to wait three weeks when you are going to talk about old news? This old news is in regards to Mipo. What you need to keep in mind is that three years out Mipo actually lowered CV major events in the worst population in the universe vs the competition that has been out for four years that has shown NO REDUCTION in major CV events. Besides that the newer generation drugs are more potent and have lesss side-effects. Don't wait three three weeks, please post our arguments/data now. t
Second day in a row that looks like big volume. t
Exelixis announces FDA approval of Cabometyx tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy (4.62 +0.21)
Cabometyx, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, 'robust and clinically meaningful improvements' in all three efficacy parameters — overall survival, progression-free survival, and objective response rate.
The most common adverse reactions in Cabometyx-treated patients include diarrhea, fatigue, nausea, decreased appetite, hand-foot syndrome, high blood pressure, vomiting, weight loss, and constipation. Dose reduction rates were 60 percent for Cabometyx and 24% for everolimus
The rate of treatment discontinuation due to adverse reactions was low (10% in each arm) and consistent with that previously reported for everolimus
Exelixis management will discuss the Cabometyx U.S. regulatory approval during a conference call beginning at 4:00 p.m. EDT/1:00 p.m. PDT today, April 25, 2016
This drug is much farther along that Archexin. It works in a different way and the two could be compatible and used together. OPDIVO just got approved for RCC in Canada today and works in still a different way as a check point inhibitor. This drug from EXEL is notably better in regards to side-effects compared to OPDIVO and PFE's drug for RCC as well. Interesting array of drugs coming out for RCC. Price of the drug will be important as well. t
You really make yourself look bad with that last post as everything points to yourself. You are trying to draw attention away from yourself as most everyone know's on this board that you chums are really one person. You use the words prostitute yourself when in fact people here are just trying to improve their lot in life. They aren't here for a decade and the only real reason why you have been here more than a decade is that you get money for it, or you are mentally unstable. As far as your show one approved drug "rule" there are so many drugs that could be out in the next three years from this very improved technology that not many big pharmas will be able to match that rate. You have not kept up with technology. You need to go out and stop Congress from developing any of those self-driving cars because there hasn't been one approved to ride on the freeway yet. Keep your beliefs "pure." t
Please post the message where I recommended the stock at $70 and $75 dollars to really prove that you aren't a liar. Should be "easy" to find. t
You have some kind of weird hate for IONS. That is not my business. This is an information board and you have received accurate information about true products that are being proven to be effective and valuable. Anything you talk about from twenty years back today without real info to back you up will haunt you very badly and very shortly. Dr. Crooke started the company in his garage and he is the second person in the world to really endorse RNA medicine besides that guy who died about three years ago at the age of 93. You are about to be really compromised financially if you are shorting the stock. If you have no skin in the game but this is your profession.....bad mouthing IONS you are about to become illegitimate. t
This the market and stocks go up and down. IOBS however is very stable price-wise. You will be in for some back-peddling very soon. You carry a liability risk for yourself. How about quoting how much cash they have on hand vs. what they had last year?! t
It should be somewhat easy for Archexin to compete price-wise with what is out there now. Immunotherapy has still a lot of side-effects and still so far appears not to break that 15% response rate in patient's with Stage IV RCC:
Immunotherapy for Metastatic Renal Cell Cancer: Immunotherapy works by stimulating the immune system to fight the cancer. The two most frequently used types of immunotherapy are Proleukin® (interleukin-2) and alfa interferon.
Proleukin® (interleukin-2): Prior to the FDA-approval of new targeted therapies, Proleukin was the standard of care for patients with renal cell cancer. It is typically administered in high doses as an inpatient treatment and has historically been associated with severe side effects. However, the safety of high-dose Proleukin has significantly improved over the past decade.
Unfortunately, long-term results of clinical trials indicate that only approximately 15% of patients with advanced renal cell carcinoma have an anticancer response when treated with high-dose Proleukin.4 For this reason the combination of targeted therapy plus Proleukin is being evaluated in clinical trials.
Interferon: Interferon is naturally produced in the body and stimulates the immune system. Interferon alfa is a compound produced in a laboratory that mimics the action of natural interferon and has been shown to stimulate the immune system to recognize and destroy some types of cancer cells.
Treatment of renal cell carcinoma with interferon appears to produce anticancer responses in less than 15% of patients with advanced renal cell cancer. Because side effects can be severe and it has not been shown to improve survival, the use of interferon alone in the treatment of renal cell carcinoma remains controversial.
Of course remember this is only one of the three drugs and for only one indication that RNN has to offer. When one looks at CPXX and why it went up so much and is able to hold onto those gains the basics are fairly simple. Their drug actually increased over-all survival by about three months over the present standard of care, the so-called 7 +3 cancer treatment regimen fo patients withr AML. These results were impressive and they were Phase III. Vyxeos, the drug name for CPXX drug also had side-effects similar to 7 + 3. Thus this could really move up to be first line therapy. The bar is set kind of low based on the poor prognosis with AML. You now have a drug that is better with about the same side-effect profile. Now with Archexin going for the indication for RCC if you look at Stage IV RCC patient's this bar is also set very low. Only 10-15% of the patient's in this group end-up responding to chemotherapy. With Archexin and the other RNN drugs safety record that is a no-brainer in that regard. What we need to see is something like the CPXX drug with Phase III data that shows at least a 4 month survival advantage with that excellent safety record that all of these drugs have exhibited that RNN has and we could see IMO a very similar situation for RNN based on the poor prognosis for patient's with Stage IV RCC, and the poor response to the present therapy. So some lines of comparison can be drawn even if not exact. We can get somewhat of a gauge of what wall street would like to
see based on this overview of the CPXX drug. t
You've really made terrible calls on what is going on with IONS. You've been saying down into the 30's for over two months, You also really called this Monday's action completely wrong by a huge amount. Over time your "correctness" will be even more off. t
IONS is picking up important neurology expertise that may allow them to go off on their own for a lot of different neurological conditions that they otherwise wouldn't have been able to go after. The other partners in their agreement for biomarkers and targets for neurological diseases have not fared as well as IONS. Including with that was FOLD and SGMO. IONS will get $100 K for each target and I believe 5% royalty on any drug that uses their discovered target but BIIB actually uses one of the competitors drugs instead. t
Have never said a thing about the fat life......you are approaching politician mentality. This is an information board. t
Jared you really exposed yourself....now you really should go away and let people who want to talk about this as an investment, both sides, and truthfully have that opportunity. You are in the wrong place for some many reasons. t
Look into the Goldman Sach's Comference and their willing to sell the Hemophilia drugs and redeploy those funds in their neuro targets with IONS. Including Alzheimer Disease and ALS. t
Jared, you have your own board for porno. Keep it up while you grind about IONS as IONS grinds it out on important diseases like Alzheimer Disease so as you get more demented every year...even more than you are now......When you are in the big house you really only need a two word vocabulary though anyway...that being, 'yes Bubba.' t